Slide 1: Investor Presentation
INVESTOR PRESENTATION 23 OCTOBER 2018
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This document has been prepared by Innate Pharma S.A. (the implied, is made as to, and no reliance should be placed on, “Company”) solely for the purposes of a presentation to the fairness, accuracy, completeness or correctness of the investors concerning the Company. This
Slide 3: Transaction Highlights: Acceleration of Innate Pharma's Strategy
TRANSACTION HIGHLIGHTS ACCELERATION OF INNATE PHARMA’S STRATEGY 1 2 3 Innate Pharma (“IPH”) to Lumoxiti, Building become fully integrated an innovative treatment rare cancers franchise oncology-focused for relapsed/refractory & leveraging synergy biotech HCL patients with IPH4102 4 5 6 Following pro
Slide 4: Transaction Summary – Key Components
TRANSACTION SUMMARY – KEY COMPONENTS BUILDING LONG-TERM STRATEGIC PARTNERSHIP IPH acquires US & EU rights to Lumoxiti with staged collaborative transition 1 of operations from AZ(1,2) AZ will obtain full oncology rights to monalizumab, expanding 2 its partnership pursuant to the 2015 agreement IPH t
Slide 5: IPH Portfolio: Broad & Balanced Immuno-Oncology Franchise
IPH PORTFOLIO BROAD & BALANCED IMMUNO-ONCOLOGY FRANCHISE IPH Proprietary Portfolio / Pipeline IPH Partnered Pipeline Pre- Dose Signal Upcoming Pre- Dose Signal Upcoming Product Indications clinical Escalation Detection Pivotal Approved Events Product Indications clinical Escalation Detection Pivotal
Slide 6: Lumoxiti – A Strategic First Step to Build a Commercial Portfolio
LUMOXITI – A STRATEGIC FIRST STEP TO BUILD A COMMERCIAL PORTFOLIO BRINGING INNOVATIVE TREATMENT TO PATIENTS First-In-Class Treatment for HCL Significant Near-Term Opportunity Label • Approved under FDA priority review Filing in the EU expected in Imminent launch in the US H2 2019 • Adult patients wi
Slide 7: Lumoxiti – Studied in the Largest Trial to Date in R/R HCL
LUMOXITI – STUDIED IN THE LARGEST TRIAL TO DATE IN PATIENTS WITH R/R HCL CLINICAL PERFORMANCE VS. BENCHMARKS Unmet Medical Need In HCL Clinical Performance vs. Benchmarks(1) Moxetumomab Vemurafenib(2) Ibrutinib(2) Rituximab(2) PNA(4) Pasudotox Durable CR N=80 N=28 & 26 N=28 N=24 N<30 INV 51.3% 35% &
Slide 8: Lumoxiti – Estimated US Patient Population
LUMOXITI – ESTIMATED US PATIENT POPULATION TREATMENT DETERMINED BY DURATION OF RESPONSE TO PREVIOUS THERAPY Treatment Option Estimated Number of Patients 1st Line Treatment PNA – Cladribine or Pentostatine ~950 Treatment Option Estimated Number of Patients 2nd Line • Relapse > 2 years – Retreat with
Slide 9: Lumoxiti – IPH Has Full Commercial Rights to US and EU Territories
LUMOXITI – IPH HAS FULL COMMERCIAL RIGHTS TO US AND EU TERRITORIES STAGED COLLABORATIVE TRANSITION WITH AZ • In agreement with IPH, AZ will commercialize Lumoxiti in the US up to mid-2020, with IPH beginning co-commercialization activity in mid-2019 US Rights o $10m sales milestone • IPH is responsi
Slide 10: Monalizumab – In Combination with Cetuximab in R/R SCCHN
MONALIZUMAB – IN COMBINATION WITH CETUXIMAB IN R/R SCCHN ENCOURAGING CLINICAL DATA PRESENTED AT ESMO Monalizumab+ Cetuximab Pembrolizumab Nivolumab Cetuximab N patients 40 103 247 240 ORR 27.5% 12.6% 14.6% 13.3% Med. PFS 5.0 mo 2.3 mo 2.1 mo 2.0 mo Median OS 10.3 mo 5.8 mo 8.4 mo 7.5 mo Fayette et a
Slide 11: Expanded Research Collaboration with AZ
EXPANDED RESEARCH COLLABORATION WITH AZ VALIDATES IPH’S LEADING IMMUNO-ONCOLOGY PLATFORM IPH5201 (anti-CD39) Research Collaborations – Key Terms Anti-CD39 antibody Overview ● IPH to grant AZ the option to an exclusive license to Blocks the enzyme activity of both soluble and Rights Granted IPH52
Slide 12: Financial Terms – Transaction Strengthens IPH's Cash Position
FINANCIAL TERMS – TRANSACTION STRENGTHENS IPH’S CASH POSITION AND ABILITY TO INVEST IN ITS PIPELINE AND PLATFORM Payments by AZ Payments by IPH Monalizumab IPH5201 Additional 4 Preclinical Molecules Lumoxiti • Opt-in Payment: • Upfront Payments: • Upfront Payments: • Upfront Payments > USD100m > USD
Slide 13: Transaction Highlights: Acceleration of Innate Pharma's Strategy
TRANSACTION HIGHLIGHTS ACCELERATION OF INNATE PHARMA’S STRATEGY 1 2 3 Lumoxiti, Building IPH to become an innovative treatment rare cancers franchise fully integrated oncology- for relapsed/refractory & leveraging synergy focused biotech HCL patients with IPH4102 4 5 6 Following promising Expansion